SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Business
Newly Stacked PhRMA to Meet With Trump on IRA, Other Policies
The meeting, which will include Pfizer CEO Albert Bourla as the newly named board of directors’ chair, will reportedly cover key topics for the lobbying group, including the Inflation Reduction Act.
February 20, 2025
 · 
2 min read
 · 
Kate Goodwin
Businessman climbed the clouds to see the distance
Immunology and Inflammation
I&I Investment Ramps Up With Novel Targets and Boundless Opportunity
Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options in inflammatory bowel disease, atopic dermatitis, myasthenia gravis and more.
February 17, 2025
 · 
5 min read
 · 
Kate Goodwin
AbbVie's office in South San Francisco, California
Deals
AbbVie Triples Down on T Cell Therapies in Xilio Deal Worth Up to $2.1B
The pharma giant inked its third T cell engager deal of 2025 Wednesday—this time with Xilio Therapeutics for tumor-activated immunotherapies.
February 12, 2025
 · 
1 min read
 · 
Kate Goodwin
Financial Crisis Concept. Bankrupt Businessman Character Stand at Sinking Paper Ship Waving White Flag in Sea with scatter Dollar Bills and Coins Business Man Bankruptcy. Cartoon Vector Illustration
Layoffs
Novo Partner Omega Waves Bankruptcy Flag from Sinking Ship
Just over a year after striking an obesity deal with Novo Nordisk, an SEC filing shows Flagship Pioneering spinout Omega Therapeutics is days away from bankruptcy and will lay off up to 17 employees.
February 4, 2025
 · 
1 min read
 · 
Kate Goodwin
Back view of disabled teenager in wheelchair looking out window, having depression at home, copy space. Paraplegic teen boy feeling stressed and upset, suffering from loneliness indoors
Duchenne muscular dystrophy
5 DMD Candidates to Watch in 2025
Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and more aim to deliver the next wave of progress with near-term data and regulatory milestones.
January 27, 2025
 · 
6 min read
 · 
Kate Goodwin
Histology microscope image of motor unit synapse of muscle fibers (100x)
Duchenne muscular dystrophy
Duchenne Muscular Dystrophy Space on Cusp of Pivotal Era
While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several companies including Wave, Dyne and Avidity are looking to answer the call with investigational therapies targeting greater efficacy and broader reach.
January 27, 2025
 · 
8 min read
 · 
Kate Goodwin
Cancer cells
Cancer
Reframing Multiple Myeloma: From Fatal to Chronic and Even Curable
Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, bispecifics and more contributing to multifaceted regimens unique to each patient’s needs.
January 21, 2025
 · 
8 min read
 · 
Kate Goodwin
Drug Development
Could New Leqembi Formulations Boost Lagging Sales in Alzheimer’s?
The FDA accepted Biogen and Eisai’s BLA for a subcutaneous administration of the anti-amyloid antibody Monday as the partners await the regulator’s decision on a new intravenous regimen following an underwhelming launch riddled with coverage and accessibility barriers.
January 14, 2025
 · 
1 min read
 · 
Kate Goodwin
Regulatory
Keytruda and Opdivo Scrutiny Highlights FDA’s Evolving Biomarker Focus
An FDA committee’s September 2024 vote to limit the use of Merck’s Keytruda and BMS’ Opdivo in stomach and esophageal cancers based on PD-L1 expression levels reflects an emerging trend that leverages ever-maturing datasets.
January 13, 2025
 · 
5 min read
 · 
Kate Goodwin
Heart human anatomy anatomical pottery neutral backgrounds soft tones beige brown background 3d illustration render digital rendering
Cardiovascular disease
Marea Posts Positive Phase II Data for Remnant Cholesterol Lowering mAb
Research has shown remnant cholesterol is a significant factor in cardiovascular disease risk.
January 10, 2025
 · 
1 min read
 · 
Kate Goodwin
GLP-1
Evidence Mounts for Benefit of GLP-1s Against Heart Disease
Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular benefits in the world’s fastest-growing drug class.
January 6, 2025
 · 
6 min read
 · 
Kate Goodwin
Traffic light in green color, with the dusk sky in the background.
FDA
2024 Ends With Greenlights for Merck’s PAH Drug in UK and BMS’ Opdivo Injection in US
Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s greenlight for an injectable formulation of BMS’s cancer blockbuster.
January 2, 2025
 · 
2 min read
 · 
Kate Goodwin
Eli Lilly's biotechnology center in California
GLP-1
Lilly’s Zepbound Snags First Ever Sleep Apnea Drug Approval
The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in combination with diet and exercise.
December 23, 2024
 · 
2 min read
 · 
Kate Goodwin
Recession arrow, Graph showing business decline on led screen
MASH
Phase III MASH Miss Sends Galectin Stock Tumbling
Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint for its Phase IIb/III trial for patients with a type of liver cirrhosis.
December 20, 2024
 · 
1 min read
 · 
Kate Goodwin
External view of Bristol Myers Squibb's office California
Alzheimer’s disease
BMS Taps Eisai’s Alzheimer’s Partner in Massive $1.35B Biobucks Deal
BioArctic received $100 million upfront with another $1.25 billion in potential milestone payments on the line for two pyroglutamate-amyloid-beta antibodies.
December 19, 2024
 · 
1 min read
 · 
Kate Goodwin
Load More